Selecta Biosciences, Inc.

Coley Pharmaceutical Gmbh

Janus Biotherapeutics, Inc.

Coley Pharmaceutical Group, Inc.

Pfizer Corporation

Zoetis Belgium S.a

Zoetis Belgium

Lipford, Grayson, B.

Zepp, Charles, M.

Grayson B Lipford

Charles M Zepp

Stefan Bauer

Jörg Vollmer

Hermann Wagner

Yun Gao

Christopher C Fraser

Lloyd Johnston

Sam Baldwin

Alexandra Forsbach

Eugen Uhlmann

Arthur Mertz Krieg

Roberto A Maldonado

Marion Jurk

David H Altreuter

Robert L Bratzler

Fen-ni Fu

Mark J Keegan

Ulrike Samulowitz

Petr Ilyinskii

Robert Rankin

Christopher J Roy

Robert Lamothe

Joerg Vollmer

Christopher Fraser

This invention relates, at least in part, to compositions comprising synthetic nanocarriers and immunosuppressants that result in immune suppressive effects. Such compositions can further comprise antigen and provide antigen-specific tolerogenic immune responses.

Tolerogenic synthetic nanocarriers

The present invention relates to a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same; and a method for treating or preventing autoimmunity disease using the same.

Immune system modulators

This invention relates to compositions, and related compounds and methods, of conjugates of immunomodulatory agents and polymers or unit(s) thereof. The conjugates may be contained within synthetic nanocarriers, and the immunomodulatory agents may be released from the synthetic nanocarriers in a pH sensitive manner.

Immunomodulatory agent-polymeric compounds

The present invention relates to a compound of Formula I: or an enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt or solvate thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same; and a method for treating or preventing autoimmunity disease using the same. 

Imidazole quinoline-based immune system modulators

Disclosed are synthetic nanocarrier compositions with coupled adjuvant compositions as well as related methods.

Dose selection of adjuvanted synthetic nanocarriers

Compositions and methods relating to immunostimulatory RNA oligomers are provided. The immunostimulatory RNA molecules are believed to represent natural ligands of one or more Toll-like receptors, including Toll-like receptor 7 (TLR7) and Toll-like receptor 8 (TLR8). The compositions and methods are useful for stimulating immune activation. Methods useful for screening candidate immunostimulatory compounds are also provided.

Immunostimulatory G, U-containing oligoribonucleotides

The present invention relates to a compound of Formula I: or a pharmaceutically acceptable salt thereof, wherein the symbols are as defined in the specification; a pharmaceutical composition comprising the same; and a method for treating or preventing autoimmunity disease using the same. 

Growing community of inventors

Watertown, MA, United States of America

Grayson B Lipford